Several other research firms have also issued reports on SNY. BidaskClub raised shares of Sanofi from a hold rating to a buy rating in a research note on Friday, June 23rd. Zacks Investment Research raised shares of Sanofi from a hold rating to a buy rating and set a $55.00 price objective for the company in a research note on Friday, June 2nd. HSBC Holdings plc raised shares of Sanofi from a reduce rating to a hold rating in a research note on Wednesday, August 30th. Argus reaffirmed a buy rating and issued a $55.00 price objective on shares of Sanofi in a research note on Friday, September 1st. Finally, Cowen and Company reaffirmed a market perform rating and issued a $52.00 price objective (up previously from $46.00) on shares of Sanofi in a research note on Tuesday, August 1st. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have given a buy rating to the company. The company has an average rating of Hold and a consensus target price of $54.00.
Shares of Sanofi (SNY) opened at 48.64 on Friday. The company has a 50-day moving average price of $48.33 and a 200 day moving average price of $47.42. The firm has a market capitalization of $122.16 billion, a P/E ratio of 11.34 and a beta of 0.88. Sanofi has a one year low of $36.81 and a one year high of $50.24.
Sanofi (NYSE:SNY) last released its quarterly earnings data on Monday, July 31st. The company reported $0.74 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.74. Sanofi had a net margin of 25.89% and a return on equity of 25.34%. The business had revenue of $8.66 billion during the quarter, compared to analyst estimates of $8.71 billion. The business’s revenue was down 2.3% on a year-over-year basis. Analysts expect that Sanofi will post $3.34 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This report was originally published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://www.chaffeybreeze.com/2017/09/19/sanofi-sny-rating-reiterated-by-j-p-morgan-chase-co.html.
In other news, major shareholder Sanofi bought 60,595 shares of the company’s stock in a transaction that occurred on Wednesday, August 23rd. The shares were purchased at an average price of $478.98 per share, for a total transaction of $29,023,793.10. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 1.00% of the company’s stock.
Several large investors have recently bought and sold shares of SNY. Bank of New York Mellon Corp increased its holdings in shares of Sanofi by 1.0% during the 1st quarter. Bank of New York Mellon Corp now owns 305,326 shares of the company’s stock worth $13,816,000 after purchasing an additional 3,013 shares during the period. BNP Paribas Arbitrage SA increased its holdings in shares of Sanofi by 69.8% during the 1st quarter. BNP Paribas Arbitrage SA now owns 17,692 shares of the company’s stock worth $801,000 after purchasing an additional 7,275 shares during the period. TD Asset Management Inc. increased its holdings in shares of Sanofi by 7.9% during the 1st quarter. TD Asset Management Inc. now owns 188,689 shares of the company’s stock worth $8,538,000 after purchasing an additional 13,797 shares during the period. Ameriprise Financial Inc. increased its holdings in shares of Sanofi by 8.0% during the 1st quarter. Ameriprise Financial Inc. now owns 495,865 shares of the company’s stock worth $22,421,000 after purchasing an additional 36,873 shares during the period. Finally, Eagle Asset Management Inc. bought a new position in shares of Sanofi during the 1st quarter worth about $260,000. Institutional investors own 9.33% of the company’s stock.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.